Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

25 citing papers in PubMed.

1. Molecular Mechanism of Tau Misfolding and Aggregation: Insights from Molecular Dynamics Simulation.Current medicinal chemistry · 2024
   Review
2. Amyloid β-based therapy for Alzheimer's disease: challenges, successes and future.Signal transduction and targeted therapy · 2023
   Review
3. Recent Trends in Active and Passive Immunotherapies of Alzheimer's Disease.Antibodies (Basel, Switzerland) · 2023
   Review
4. Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy.Molecular neurodegeneration · 2021
   Article
5. Neuroimmune crosstalk and evolving pharmacotherapies in neurodegenerative diseases.Immunology · 2021
   Review
6. Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV-1959D to enter the first-in-human clinical trials.Neurobiology of disease · 2020
   Review
7. Analysis of the Consolidation Phase of Immunological Memory within the IgG Response to a B Cell Epitope Displayed on a Filamentous Bacteriophage.Microorganisms · 2020
   Article
8. The Role of microRNAs in Alzheimer's Disease and Their Therapeutic Potentials.Genes · 2018
   Review
9. Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development.Frontiers in neuroscience · 2018
   Review
10. Efficacy and safety of anti-amyloid-Annals of clinical and translational neurology · 2017
    Review
11. Improving Memory and Cognition in Individuals with Down Syndrome.CNS drugs · 2016
    Review
12. Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges.Molecular neurodegeneration · 2016
    Review
13. Developing therapeutic vaccines against Alzheimer's disease.Expert review of vaccines · 2016
    Review
14. Overexpression of Swedish mutant APP in aged astrocytes attenuates excitatory synaptic transmission.Physiological reports · 2016
    Article
15. A fresh perspective from immunologists and vaccine researchers: active vaccination strategies to prevent and reverse Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2015
    Review
16. Advances in Alzheimer's disease drug development.BMC medicine · 2015
    Review
17. Immunotherapeutic approaches for Alzheimer's disease.Neuron · 2015
    Review
18. Immunotherapy for Alzheimer's disease.Biochemical pharmacology · 2014
    Review
19. Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?ImmunoTargets and therapy · 2014
    Review
20. Novel immunological approaches for the treatment of Alzheimer's disease.Zhongguo xian dai shen jing ji bing za zhi · 2014
    Article

Corrections and comments

• Comment on
  Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.2008

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as